Rin1 is a negative regulator of the IL3 receptor signal transduction pathways

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 905-916

  Hunker, C M ^a   Galvis, A ^a   Veisaga, M L ^a   Barbieri, M A ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

BCR ABL; Ras; Rin1; Signal transduction

Indexed keywords

BCR ABL PROTEIN; INTERLEUKIN 3; INTERLEUKIN 3 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; PROTEIN RIN1; RAS PROTEIN; STRESS ACTIVATED PROTEIN KINASE; THYMIDINE; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL GROWTH PROCESSES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FUSION PROTEINS, BCR-ABL; GENE DELETION; HL-60 CELLS; HUMANS; INTERLEUKIN-3; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; K562 CELLS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RECEPTORS, INTERLEUKIN-3; SIGNAL TRANSDUCTION;

EID: 33645821701     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Lee JT Jr and McCubrey JA: The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 16(4): 486-507, 2002.
2. McCubrey JA et al: Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Detect Prev 25(4): 375-393, 2001.
3. Hantschel O and Superti-Furga G: Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 5(1): 33-44, 2004.
4. 2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 189(8): 1229-1242, 1999.
5. Neshat MS et al: The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3- kinase and Raf. Mol Cell Biol 20(4): 1179-1186, 2000.
6. Pendergast AM et al: SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol 13(3): 1728-36, 1993.
7. Pendergast AM et al: BCR sequences essential for transformation by the BCRABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine- dependent manner. Cell 66(1): 161-71, 1991.
8. Sirard C, Laneuville P and Dick JE: Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 83(6): 1575-1585, 1994.
9. Sillaber C et al: STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 95(6): 2118-2125, 2000.
10. de Groot RP et al: STATS activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 94(3): 1108-1112, 1999.
11. Ben-Neriah Y et al: The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233(4760): 212-214, 1986.
12. Sawyers CL: Chronic myeloid leukemia. N Engl J Med 340(17): 1330-1340, 1999.
13. Faderl S et al: The biology of chronic myeloid leukemia. N Engl J Med 341(3): 164-172, 1999.
14. Frank DA and Varticovski L: BCR/Abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia 10(11): 1724-1730, 1996.
15. Sawyers CL, Denny CT and Witte ON: Leukemia and the disruption of normal hematopoiesis. Cell 64(2): 337-350, 1991.
16. Calabretta B and Skorski T: Gene regulatory mechanisms operative on hematopoietic cells: proliferation, differentiation, and neoplasia. Crit Rev Eukaryot Gene Expr 7(1-2): 117-124, 1997.
17. Tenen DG et al: Transcription factors, normal myeloid development, and leukemia. Blood 90(2): 489-519, 1997.
18. Donate NJ et al: Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood 97(9): 2846-2853, 2001.
19. Luo JM et al: Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 17(1): 1-8, 2003.
20. Sattler M et al: Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1(5): 479-492, 2002.
21. Afar DE et al: Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity 6(6): 773-782, 1997.
22. Barbieri MA et al: Role of rab5 in EGF receptor-mediated signal transduction. Eur J Cell Biol 83(6): 305-314, 2004.
23. Tall GG et al: Ras-activated endocytosis is mediated by the Rab5 guanine nucleotide exchange activity of RIN1. Dev Cell 1(1): 73-82, 2001.
24. Barbieri MA et al: The SRC homology 2 domain of Rin1 mediates its binding to the epidermal growth factor receptor and regulates receptor endocytosis. J Biol Chem 278(34): 32027-3236, 2003.
25. Barbieri MA et al: Epidermal growth factor and membrane trafficking. EGF receptor activation of endocytosis requires Rab5a. J Cell Biol 151(3): 539-550, 2000.
26. Traina F et al: BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells. FEBS Lett 535(1-3): 17-22, 2003.
27. 2 domains. Cell Signal 72(5): 183-194, 2000.
28. Steelman LS et al: JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18(2): 189-218, 2004.
29. Mizuchi D et al: BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells. Biochem Biophys Res Commun 526(5): 645-651, 2005.
30. Skorski T et al: Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16(20): 6151-6161, 1997.
31. McFarlin DR, Lindstrom MJ and Gould MN: Affinity with Raf is sufficient for Ras to efficiently induce rat mammary carcinomas. Carcinogenesis 24(1): 99-105, 2003.